Abstract
Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown a high response rate and long progression-free survival in primary treatment of ALK-positive non-small-cell lung cancer (NSCLC). De novo resistance or refractory subtype is rare event. Herein, we identify the first case with serial next-generation sequencing (NGS) results that harboured a rare echinoderm microtubule associated protein like 4 gene (EML4) -ALK (breaking site at exon 19) fusion in a lung adenocarcinoma (LUAD) patient who acquired alectinib resistance rapidly (less than 3 months), followed by multi-drug resistance and short survival time.
Original language | English (US) |
---|---|
Pages (from-to) | 32-35 |
Number of pages | 4 |
Journal | Lung Cancer |
Volume | 160 |
DOIs | |
State | Published - Oct 2021 |
Keywords
- ALK TKIs
- ALK variants
- Case report
- Lung cancer
ASJC Scopus subject areas
- Oncology
- Pulmonary and Respiratory Medicine
- Cancer Research